Impact of age and histological type on programmed death-ligand 1 expression in non-small cell lung cancer – a single-center analysis of 1,606 cases
Polish Journal of Pathology · 2025
DOI: 10.5114/pjp.2025.157974 ↗Kurz gefasst
Fachartikel in der Zeitschrift Polish Journal of Pathology, 2025. Verfasst von Anna Szumera-Ciećkiewicz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biobank, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Biomarkers, Tumor.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1) guides immune checkpoint inhibitor use in non-small cell lung cancer (NSCLC), yet its variation by age and histology remains uncertain. We retrospectively evaluated 1,606 consecutive NSCLC cases (2017-2022) with PD-L1 immunohistochemistry (IHC) on formalin-fixed, paraffin- embedded samples. Patients were grouped by age (< 60, 60-79, ≥ 80 years) and tumor proportion score (TPS), categorized as < 1%, 1-49%, or ≥ 50%. Associations were tested using the ² test, and independent predictors were identified using multinomial logistic regression. High PD-L1 expression (TPS ≥ 50%) occurred in 33.6% of patients, intermediate (1-49%) in 23.6%, and negative (< 1%) in 42.7%. Programmed death-ligand 1 expression ≥ 1% was most frequent in squamous cell carcinoma (63.0%), followed by adenocarcinoma (55.0%), and was least common in large cell carcinoma (36.0%; p = 0.002). Overall proportions of PD-L1 ≥ 1% did not differ significantly by age. However, patients aged ≥ 80 had nearly twice the likelihood of high expression compared to those < 60 (relative risk ratio, 1.92; 95% CI: 1.11-3.34; p = 0.02), independent of the histotype. Programmed death-ligand 1 expression in NSCLC shows distinct histotype-related patterns and a modest, age-related trend toward higher values in the oldest group. These data support routine PD-L1 assessment and suggest that advanced age alone should not preclude consideration of immunotherapy. Findings may inform trial design and real-world treatment decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biobank, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Pathology, Military Medical Institute, Warsaw, Poland.
- Department of Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Digital Medicine Center, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Lung Cancer and Chest Tumors, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Zitieren
APA
Szumera-Ciećkiewicz, A., Wiśniewski, P., Tomczyk-Szatkowska, A., Rosińska, M., Pierzchała, D., Owczarek, J., Winiarczyk, K., Wołoszyn, P., Krzakowski, M., & Knetki-Wróblewska, M. (2025). Impact of age and histological type on programmed death-ligand 1 expression in non-small cell lung cancer – a single-center analysis of 1,606 cases. Polish Journal of Pathology. https://doi.org/10.5114/pjp.2025.157974
Vancouver
Szumera-Ciećkiewicz A, Wiśniewski P, Tomczyk-Szatkowska A, Rosińska M, Pierzchała D, Owczarek J, et al. Impact of age and histological type on programmed death-ligand 1 expression in non-small cell lung cancer – a single-center analysis of 1,606 cases. Polish Journal of Pathology. 2025. doi:10.5114/pjp.2025.157974
BibTeX
@article{SzumeraCiekiewicz2025,
author = {Szumera-Ciećkiewicz, Anna and Wiśniewski, Piotr and Tomczyk-Szatkowska, Agnieszka and Rosińska, Magdalena and Pierzchała, Dorota and Owczarek, Joanna and Winiarczyk, Kinga and Wołoszyn, Patrycja and Krzakowski, Maciej and Knetki-Wróblewska, Magdalena},
title = {Impact of age and histological type on programmed death-ligand 1 expression in non-small cell lung cancer – a single-center analysis of 1,606 cases},
journal = {Polish Journal of Pathology},
year = {2025},
doi = {10.5114/pjp.2025.157974}
}
EUVIMED